These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10990150)

  • 21. Hexarelin induced growth hormone release is influenced by exogenous growth hormone.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):617-21. PubMed ID: 8548947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs.
    Rigamonti AE; Cella SG; Marazzi N; Müller EE
    Metabolism; 1999 Feb; 48(2):176-82. PubMed ID: 10024078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced Pulsatile Growth Hormone Secretion and Altered Metabolic Hormones by in Vivo Hexarelin Treatment in Streptozotocin-Induced Diabetic Rats.
    Zhang X; Yang JK; Chen C
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac effects of hexarelin in hypopituitary adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Aimaretti G; Pelosi E; Del Rio G; Muccioli G; Ong H; Boghen MF; Deghenghi R; Ghigo E
    Eur J Pharmacol; 1999 Sep; 381(1):31-8. PubMed ID: 10528131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.
    Conley LK; Brogan RS; Giustina A; Wehrenberg WB
    Pituitary; 2000 May; 2(4):253-60. PubMed ID: 11081146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oestrogen replacement does not restore the reduced GH-releasing activity of Hexarelin, a synthetic hexapeptide, in post-menopausal women.
    Arvat E; Gianotti L; Broglio F; Maccagno B; Bertagna A; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1997 May; 136(5):483-7. PubMed ID: 9186268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
    Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
    Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.
    Arosio M; Casati G; Biella O; Porretti S; Imbimbo BP; Faglia G
    J Endocrinol Invest; 1998 Apr; 21(4):239-44. PubMed ID: 9624598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
    Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D; Popovic V; Kendereski A; Peino R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.
    Popovic V; Micic D; Djurovic M; Obradovic S; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1997 May; 46(5):539-43. PubMed ID: 9231048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency.
    Gill MS; Toogood AA; O'Neill PA; Thorner MO; Shalet SM; Clayton PE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2562-5. PubMed ID: 9661643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
    Arvat E; Di Vito L; Lanfranco F; Broglio F; Giordano R; Benso A; Muccioli GP; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).
    Laron Z; Frenkel J; Gil-Ad I; Klinger B; Lubin E; Wuthrich P; Boutignon F; Lengerts V; Deghenghi R
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):539-41. PubMed ID: 7955465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.
    Rossoni G; Locatelli V; Gennaro Colonna Vd ; Müller EE; Berti F
    Pharmacol Res; 2000 Aug; 42(2):129-36. PubMed ID: 10887041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth hormone-independent cardioprotective effects of hexarelin in the rat.
    Locatelli V; Rossoni G; Schweiger F; Torsello A; De Gennaro Colonna V; Bernareggi M; Deghenghi R; Müller EE; Berti F
    Endocrinology; 1999 Sep; 140(9):4024-31. PubMed ID: 10465272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.